PPARγ agonists and coronary atherosclerosis

Current Atherosclerosis Reports

Volumn 10, Issue 2, 2008, Pages 134-141

  Sulistio, Melanie S ^a   Zion, Adrienne ^b   Thukral, Nandish ^b   Chilton, Robert ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLITAZONE DERIVATIVE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; DIET THERAPY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; MAXIMUM TOLERATED DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; RESTENOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STENT;

ANIMALS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FATTY ACIDS, NONESTERIFIED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STENTS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 41749118732     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0020-4     Document Type: Review

References (55)

1. Hamman RF, Wing RR, Edelstein SL, et al.: Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006, 29:2102-2107.
2. Semple RK, Chaterjee VK, O'Rahilly S: PPARa and human metabolic disease. J Clin Invest 2006, 116:581-589.
3. Auboeuf D, Rieusset J, Fajas L, et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997, 46:1319-1327.
4. Finck BN: The PPAR regulatory system in cardiac physiology and disease. Cardiovasc Res 2007, 73:269-277.
5. Gearing KL, Göttlicher M, Teboul M, et al.: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 1993, 90:1440-1444.
6. Tugwood JD, Issemann I, Anderson RG, et al.: The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992, 2:433-439.
7. Krogsdam AM, Nielsen CA, Neve S, et al.: Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. Biochem J 2002, 363(Pt 1):157-165.
8. Dichtl W, Nilsson L, Goncalves I, et al.: Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999, 84:1085-1094.
9. Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
10. Marx N, Schönbeck U, Lazar MA, et al.: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998, 83:1097-103.
11. Takeda K, Ichiki T, Tokunou T, et al.: Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000, 102:1834-1839.
12. Goetze S, Xi XP, Graf K, et al.: Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett 1999, 452:277-282.
13. Wang CC, Goalstone ML, Draznin B: Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53:2735-2740.
14. Hsueh WA, Law RE: Insulin signaling in the arterial wall. Am J Cardiol 1999, 84(1A):21J-24J.
15. Miyazaki Y, He H, Mandarino LJ, et al.: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003, 52:1943-1950.
16. Arslanian SA, Lewy V, Danadian K, et al.: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002, 87:1555-1559.
17. Bailey CJ, Turner RC: Metformin. N Engl J Med 1996, 334:574-579.
18. Kim JK, Fillmore JJ, Gavrilova O, et al.: Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/ F-1 fatless mice. Diabetes 2003, 52:1311-1318.
19. Norris AW, Chen L, Fisher SJ, et al.: Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003, 112:608-618.
20. Hevener AL, He W, Barak Y, et al.: Muscle-specific PPARg deletion causes insulin resistance. Nat Med 2003, 9:1491-1497.
21. Sethi S, Eastman AY, Eaton JW: Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism? J Lab Clin Med 1996, 128:27-38.
22. Sethi S, Ziouzenkova O, Ni H, et al.: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100:1340-1346.
23. Nohé B, Johannes T, Dieterich HJ: Antiinflammatory effects of omega-3 fatty acids vary at different stages of inflammation. Am J Physiol Heart Circ Physiol 2003, 285: H2248-H2249.
24. Murray AJ, Panagia M, Hauton D, et al.: Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005, 54:3496-3502.
25. Neubauer S, Horn M, Cramer M, et al.: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
26. Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
27. Schlierf G, Dorow E: Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973, 52:732-740.
28. Szczepaniak LS, Dobbins RL, Metzger GJ, et al.: Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 2003, 49(3):417-423.
29. Bocos C, Göttlicher M, Gearing K, et al.: Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol 1995, 53(1-6):467-473.
30. Rodríguez VM, Portillo MP, Picó C, et al.: Olive oil feeding up-regulates uncoupling protein genes in rat brown adipose tissue and skeletal muscle. Am J Clin Nutr 2002, 75:213-220.
31. McGavock JM, Victor RG, Unger RH, et al.: Adiposity of the heart, revisited. Ann Intern Med 2006, 144:517-524.
32. Collins AR, Meehan WP, Kintscher U, et al.: Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:365-371.
33. Zierath JR, Ryder JW, Doebber T, et al.: Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998, 139:5034-5041.
34. Kim SY, Kim HI, Park SK, et al.: Liver glucokinase can be activated by peroxisome proliferator-activated receptor-gamma. Diabetes 2004, 53(Suppl 1):S66-S70.
35. Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054.
36. de Winther MP, Kanters E, Kraal G, et al.: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904-914.
37. Calnek DS, Mazzella L, Roser S, et al.: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:52-57.
38. Daynes RA, Jones DC.: Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002, 2:748-759.
39. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169: 453-459.
40. Ricote M, Li AC, Willson TM, et al.: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
41. Pasceri V, Wu HD, Willerson JT, et al.: Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101:235-248.
42. Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001, 21:372-377.
43. Nagashima K, Lopez C, Donovan D, et al.: Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005, 115:1323-1332.
44. Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
45. Ting HJ, Stice JP, Schaff UY, et al.: Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 2007, 100:381-390.
46. Nordestgaard BG, Benn M, Schnohr P, et al.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
47. Wilcox R, Bousser MG, Betteridge DJ, et al.: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865-873.
48. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
49. Krall RL: Cardiovascular safety of rosiglitazone. Lancet 2007, 369:1995-1996.
50. Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
51. Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005, 48:1726-1735.
52. Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
53. Takagi T, Yamamuro A, Tamita K, et al.: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.
54. Choi D, Kim SK, Choi SH, et al.: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
55. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.